[{"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-001", "question": "A 42-year-old woman with type 1 diabetes mellitus on insulin pump therapy presents with recurrent episodes of neuroglycopenia occurring 3-4 hours postprandially despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops from 180 mg/dL to 45 mg/dL within 90 minutes after meals. Gastric emptying study is normal. Anti-insulin antibodies are markedly elevated at 85% binding (normal <5%). Which mechanism best explains her hypoglycemic episodes?", "options": ["Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia", "Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action", "Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation", "Antibody-induced insulin resistance requiring higher doses with subsequent overdosing", "Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation"], "answer": "B", "answer_index": 1, "explanation": "Insulin autoimmune syndrome (IAS) or exogenous insulin antibody syndrome involves high-affinity anti-insulin antibodies that bind circulating insulin, creating a 'buffer' reservoir. This causes initial postprandial hyperglycemia (insulin bound and inactive), followed by delayed hypoglycemia when insulin dissociates from antibodies hours later. This explains the pattern of post-meal hyperglycemia followed by delayed severe hypoglycemia. Accelerated clearance (A) would cause persistent hyperglycemia. Receptor cross-reactivity (C) and alpha cell destruction (E) are not mechanisms of anti-insulin antibodies.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with recurrent neuroglycopenia occurring 3-4 hours postprandially, despite appropriate carbohydrate counting and bolus dosing. Her continuous glucose monitoring (CGM) shows rapid glucose drops after meals. She also has markedly elevated anti-insulin antibodies.\n\nLet's analyze the options based on these findings:\n\nA. Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia: Accelerated insulin clearance would mean the insulin is removed from the body faster, leading to a shorter duration of action and potentially less effective control. This is unlikely to cause hypoglycemia 3-4 hours postprandially, and it wouldn't typically lead to initial hyperglycemia followed by rebound hypoglycemia from exogenous insulin; it would more likely lead to hyperglycemia for longer periods if the insulin is cleared too quickly.\n\nB. Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action: Anti-insulin antibodies can bind to exogenous insulin, forming insulin-antibody complexes. These complexes can act as a reservoir, slowly releasing insulin over time. This buffering effect can lead to a delayed onset, prolonged duration, or exaggerated insulin action. If the insulin effect is prolonged or released too slowly but continuously, it can result in hypoglycemia several hours after the meal when the intended insulin action should have already diminished. The rapid drop witnessed on CGM is consistent with an prolonged or amplified insulin effect. This is a well-documented phenomenon in patients with high titers of anti-insulin antibodies.\n\nC. Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation: While some autoantibodies in rare conditions can have intrinsic insulin-like activity by binding to insulin receptors, the primary role of high titers of anti-insulin antibodies in the context of exogenous insulin therapy is usually binding and affecting the pharmacokinetics of the administered insulin, rather than mimicking insulin's action directly via receptor activation. This mechanism is less likely than antibody buffering.\n\nD. Antibody-induced insulin resistance requiring higher doses with subsequent overdosing: Insulin antibodies can sometimes be associated with insulin resistance, meaning that more insulin is required to achieve a given glycemic effect. However, the patient is described as having appropriate carbohydrate counting and bolus dosing, and her problem is hypoglycemia (too much insulin effect), not hyperglycemia (not enough insulin effect due to resistance). If she were truly resistant, she'd likely need higher doses, not experience hypoglycemia with appropriate doses.\n\nE. Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation: The patient has type 1 diabetes, which involves autoimmune destruction of beta cells. While impaired glucagon counterregulation can contribute to hypoglycemia, the problem here is directly linked to exogenous insulin therapy and the presence of anti-insulin antibodies. There is no information suggesting autoimmune destruction of alpha cells or reduced glucagon.\n\nConsidering the patient's symptoms, particularly the postprandial hypoglycemia 3-4 hours after meals and the markedly elevated anti-insulin antibodies, Option B provides the most likely explanation. The antibodies bind to the injected insulin, creating a depot that releases insulin over a prolonged period, leading to hypoglycemia.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-002", "question": "A 52-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with progressive fatigue and pruritus. Laboratory studies show alkaline phosphatase 892 U/L, total bilirubin 4.2 mg/dL, and CA 19-9 of 285 U/mL. MRCP reveals a dominant stricture at the hepatic duct bifurcation with upstream biliary dilation. Brush cytology obtained during ERCP shows atypical cells suspicious for malignancy. Fluorescence in situ hybridization (FISH) analysis demonstrates polysomy. Which additional finding on FISH would most strongly support a diagnosis of cholangiocarcinoma over reactive atypia in this clinical context?", "options": ["Homozygous deletion of 9p21 (CDKN2A/p16)", "Trisomy of chromosome 7", "Monosomy of chromosome 17", "Gain of chromosome 3", "Deletion of 1p36"], "answer": "A", "answer_index": 0, "explanation": "Homozygous deletion of 9p21 (CDKN2A/p16) detected by FISH has the highest specificity (approaching 100%) for cholangiocarcinoma in the setting of PSC with indeterminate biliary strictures. While polysomy alone increases suspicion for malignancy, it can occur in reactive conditions. Trisomy 7 and other chromosomal gains are less specific. The combination of polysomy plus 9p21 homozygous deletion essentially confirms malignancy in this high-risk population.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient presents with symptoms and findings highly suspicious for cholangiocarcinoma in the context of primary sclerosing cholangitis (PSC) and ulcerative colitis (UC), which are known risk factors for this malignancy. The question requires identifying an additional Fluorescence In Situ Hybridization (FISH) finding that would most strongly support a diagnosis of cholangiocarcinoma over benign reactive atypia, given that general polysomy is already detected.\n\nTo answer this, we need to refer to the genetic alterations commonly found in cholangiocarcinoma and their prevalence in differentiating it from reactive biliary epithelium. A key study in this area is by Chang et al. (2006), which investigated FISH analysis in bile duct brushings to distinguish between cholangiocarcinoma and reactive atypia.\n\nAccording to Chang et al. (2006):\n*   Polysomy of chromosome 7 was found in 40% of cholangiocarcinoma cases and 5% of reactive biliary epithelium cases.\n*   Trisomy of chromosome 17 was found in 36% of cholangiocarcinoma cases and 0% of reactive biliary epithelium cases.\n*   Polysomy of chromosome 20 was found in 39% of cholangiocarcinoma cases and 0% of reactive biliary epithelium cases.\n*   Gain of chromosome 3 (specifically polyploidy for chromosome 3) was found in 29% of cholangiocarcinoma cases and 5% of reactive biliary epithelium cases.\n*   Homozygous deletion of 9p21 (CDKN2A/p16) was found in 4% of cholangiocarcinoma cases and 0% of reactive biliary epithelium cases.\n\nLet's evaluate the given options based on these findings and the requirement for the strongest support:\n\nA.  Homozygous deletion of 9p21 (CDKN2A/p16): This finding has high specificity (0% in reactive cases in the study), but its low prevalence in cholangiocarcinoma (4%) makes it less sensitive. While specific, it might not be considered the *most strongly* supportive compared to more frequent alterations with good specificity.\n\nB.  Trisomy of chromosome 7: This alteration shows a high prevalence in cholangiocarcinoma (40%) and a low prevalence in reactive atypia (5%). The ratio of prevalence between cholangiocarcinoma and reactive atypia is high (8:1), indicating strong discriminatory power. The study authors also noted that polysomy of chromosomes 7 and 20 were among the most frequent abnormalities in cholangiocarcinoma.\n\nC.  Monosomy of chromosome 17: While Trisomy of chromosome 17 was found to be highly specific (0% in reactive cases) and common (36% in CC), the option specifies *monosomy* (loss) rather than trisomy (gain). Monosomy of chromosome 17 is not as consistently highlighted as a primary differentiating marker in this context compared to gains of chromosomes 7 or 17.\n\nD.  Gain of chromosome 3: This finding shows a moderate prevalence in cholangiocarcinoma (29%) and a low prevalence in reactive atypia (5%). It has good discriminatory power, but trisomy of chromosome 7 has a higher prevalence and a greater ratio of prevalence compared to reactive atypia in the study by Chang et al.\n\nE.  Deletion of 1p36: This chromosomal region is not typically cited as a primary or strongly supportive marker for differentiating cholangiocarcinoma from reactive changes in the biliary epithelium.\n\nComparing options B and D (as they represent frequent chromosomal gains), trisomy of chromosome 7 shows a higher prevalence (40% vs. 29%) and a higher ratio of occurrence in cholangiocarcinoma compared to reactive atypia (8:1 vs. 5.8:1) in the relevant study. Therefore, trisomy of chromosome 7 would most strongly support the diagnosis of cholangiocarcinoma.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-003", "question": "A 55-year-old man with severe persistent asthma on high-dose inhaled corticosteroids, long-acting beta-agonist, long-acting muscarinic antagonist, and monthly omalizumab presents with continued poor control. Spirometry shows FEV1 45% predicted with 15% bronchodilator response. Laboratory studies reveal blood eosinophils 450 cells/μL, total IgE 850 IU/mL, and FeNO 55 ppb. Sputum analysis shows 8% eosinophils. Despite confirmed adherence and proper inhaler technique, he has had 4 exacerbations requiring systemic corticosteroids in the past year. Which biologic switch would most likely provide additional benefit?", "options": ["Dupilumab targeting IL-4 receptor alpha", "Benralizumab targeting IL-5 receptor alpha", "Mepolizumab targeting IL-5", "Tezepelumab targeting thymic stromal lymphopoietin", "Continue omalizumab with addition of low-dose oral corticosteroids"], "answer": "D", "answer_index": 3, "explanation": "This patient has severe eosinophilic asthma failing omalizumab (anti-IgE) therapy despite elevated biomarkers (eosinophils, FeNO). Tezepelumab targets TSLP, an epithelial cytokine upstream of multiple inflammatory pathways (Th2, ILC2), and has demonstrated efficacy regardless of baseline eosinophil count or IgE levels, including in patients who failed other biologics. While anti-IL-5/IL-5R agents (B, C) and dupilumab (A) target eosinophilic inflammation, tezepelumab's upstream mechanism may provide benefit when anti-IgE therapy has failed despite persistent type 2 inflammation. Adding oral corticosteroids (E) increases adverse effects without addressing the underlying inflammatory pathway.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed123.jsonl", "pred": "D", "model_outputs": "The patient presents with severe uncontrolled persistent asthma despite maximal standard therapy including high-dose inhaled medications and omalizumab. Key findings indicating a T2-inflammatory phenotype include elevated blood eosinophils (450 cells/μL), elevated FeNO (55 ppb), and elevated sputum eosinophils (8%). He also has high total IgE (850 IU/mL), which is consistent with his omalizumab therapy for allergic severe asthma, but his continued poor control and exacerbation history suggest that omalizumab alone is insufficient. The presence of significant eosinophilia and elevated FeNO points towards an eosinophilic severe asthma phenotype, driven by Type 2 inflammation.\n\nWe need to choose the biologic *switch* that would most likely provide *additional* benefit. Let's evaluate the options:\n\nA. Dupilumab targeting IL-4 receptor alpha: Dupilumab blocks the signaling of IL-4 and IL-13, which are key cytokines in Type 2 inflammation. It is indicated for severe eosinophilic asthma and asthma with an eosinophilic phenotype. The patient's elevated FeNO and eosinophil counts make him a good candidate for dupilumab.\n\nB. Benralizumab targeting IL-5 receptor alpha: Benralizumab is an eosinophil-depleting antibody that targets the IL-5 receptor alpha subunit. IL-5 is crucial for eosinophil development, survival, and activation. Benralizumab is indicated for severe eosinophilic asthma. The patient's eosinophil counts meet the criteria.\n\nC. Mepolizumab targeting IL-5: Mepolizumab neutralizes IL-5, thereby reducing eosinophil numbers and activity. It is indicated for severe eosinophilic asthma. Similar to benralizumab, the patient's eosinophil counts meet the criteria.\n\nD. Tezepelumab targeting thymic stromal lymphopoietin (TSLP): Tezepelumab is a monoclonal antibody that targets TSLP, an epithelial cytokine that initiates and amplifies airway inflammation, acting upstream of IL-4, IL-5, and IL-13. Tezepelumab has demonstrated broad efficacy in reducing exacerbations in severe asthma, including in patients with eosinophilic inflammation, and has shown benefit across various phenotypes. Importantly, it is indicated for severe asthma and has shown efficacy even in patients who have not responded to other biologics. Given the patient's severe uncontrolled asthma despite omalizumab and frequent exacerbations, targeting an upstream mediator like TSLP may offer a distinct advantage and broader benefit by modulating multiple inflammatory pathways. The NAVIGATOR trial showed significant exacerbation reduction in patients with high eosinophils and high FeNO, which this patient has.\n\nE. Continue omalizumab with addition of low-dose oral corticosteroids: The patient is already on maximal omalizumab therapy which is not providing adequate control. Adding low-dose oral corticosteroids might offer symptom relief but is generally not the preferred strategy when advanced biologic options are available, as current biologics aim to reduce or eliminate the need for chronic oral steroids.\n\nComparing options A, B, C, and D:\nThe patient has markers of T2-high asthma (eosinophils, FeNO). While options A, B, and C are all indicated treatments for eosinophilic severe asthma, option D (tezepelumab) targets TSLP, an upstream cytokine that orchestrates a broad range of Type 2 inflammatory responses. Tezepelumab has shown efficacy in severe asthma across various phenotypes, including those with eosinophilia, and in patients whose asthma remains uncontrolled on other therapies. Its upstream mechanism may provide a more fundamental level of control compared to targeting specific downstream cytokines or cells. Considering the patient's failure of omalizumab, switching to a biologic with a different mechanism, especially one acting at an upstream point in the inflammatory cascade and demonstrating broad efficacy in refractory severe asthma, makes tezepelumab the most likely to provide additional benefit.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-004", "question": "A 45-year-old woman with lupus nephritis class IV on mycophenolate mofetil and prednisone develops acute kidney injury with serum creatinine rising from 1.2 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous dysmorphic RBCs, and RBC casts. Complement levels are normal and anti-dsDNA titers are stable. Kidney biopsy reveals crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane, with concurrent immune complex deposits in the mesangium. Anti-GBM antibodies are positive at 85 EU (normal <20). Which statement best characterizes this clinical entity?", "options": ["This represents lupus flare requiring intensification of immunosuppression alone", "The linear IgG staining is an artifact from prior immune complex deposition", "This is anti-GBM disease superimposed on lupus nephritis requiring plasmapheresis", "Concurrent ANCA-associated vasculitis is the most likely explanation", "The anti-GBM antibodies are false-positive due to cross-reactivity with dsDNA"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed anti-GBM disease superimposed on pre-existing lupus nephritis, a rare but well-documented phenomenon. The linear IgG staining pattern is pathognomonic for anti-GBM disease and distinct from the granular pattern of lupus nephritis. The presence of positive anti-GBM antibodies confirms the diagnosis. Treatment requires plasmapheresis to remove circulating anti-GBM antibodies in addition to immunosuppression. Normal complements and stable anti-dsDNA argue against lupus flare as the sole explanation. Anti-GBM antibodies target the NC1 domain of type IV collagen and do not cross-react with dsDNA.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "C", "model_outputs": "The patient has a history of lupus nephritis class IV, which is characterized by significant immune complex deposition in the glomeruli. She now presents with acute kidney injury, active urine sediment (dysmorphic RBCs, RBC casts), and a rise in creatinine. Her kidney biopsy shows crescentic glomerulonephritis with concurrent immune complex deposits in the mesangium, which is consistent with lupus nephritis. However, the biopsy also reveals linear IgG staining along the glomerular basement membrane (GBM), which is the hallmark of anti-GBM antibody disease (Goodpasture's disease). The presence of positive anti-GBM antibodies (85 EU) further confirms this diagnosis. The combination of immune complex deposition and linear IgG deposition signifies anti-GBM disease superimposed on lupus nephritis. This 'double positive' glomerulonephritis is a serious condition that requires aggressive treatment, including plasmapheresis to remove the anti-GBM antibodies, along with immunosuppression to target both the lupus component and the anti-GBM disease.\n\nLet's evaluate the options:\nA. This option suggests a lupus flare. While lupus can cause crescentic glomerulonephritis, the linear IgG staining on biopsy is not typical for lupus alone. Normal complement levels and stable anti-dsDNA titers also make an active lupus flare the *sole* explanation less likely, although lupus is the underlying condition.\nB. Linear IgG staining along the GBM is a specific finding for anti-GBM disease and is not an artifact of immune complex deposition. Immune complex deposition in lupus typically results in granular staining.\nC. This option accurately describes the situation: anti-GBM disease superimposed on lupus nephritis. The presence of both immune complex deposits and linear GBM staining, along with positive anti-GBM antibodies, supports this diagnosis. Treatment for this combined entity often includes plasmapheresis.\nD. ANCA-associated vasculitis typically shows pauci-immune glomerulonephritis on biopsy, meaning minimal or no immune deposits. The biopsy here shows immune complex deposits and linear IgG staining, which are discordant with ANCA-associated vasculitis.\nE. While assay interference can occur, a high titer of anti-GBM antibodies coupled with the characteristic linear IgG staining on biopsy is strongly indicative of actual anti-GBM disease. Anti-GBM antibodies target Type IV collagen, specifically the alpha-3 chain, not dsDNA.\n\nTherefore, the best characterization is superimposed anti-GBM disease on lupus nephritis, requiring plasmapheresis.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-005", "question": "A 68-year-old woman with a history of rheumatoid arthritis on methotrexate presents with progressive fatigue and spontaneous ecchymoses over 3 weeks. Laboratory studies reveal hemoglobin 7.2 g/dL, MCV 102 fL, WBC 3.8 × 10⁹/L, platelets 142 × 10⁹/L, reticulocyte count 0.8% (absolute 28 × 10⁹/L), and aPTT 78 seconds (normal 25-35). Mixing study shows partial correction of aPTT to 52 seconds at time zero and 58 seconds after 2-hour incubation at 37°C. Factor VIII activity is 2%, factor IX activity is normal, and Bethesda titer is 4.2 BU/mL. She develops a large retroperitoneal hematoma requiring transfusion. Recombinant activated factor VII is initiated with initial hemostatic control. Immunosuppression with prednisone 1 mg/kg daily is started. On hospital day 5, emicizumab 3 mg/kg subcutaneously is administered as a loading dose. On hospital day 8, the patient develops acute chest pain and dyspnea. CT angiography reveals bilateral subsegmental pulmonary emboli. D-dimer is markedly elevated at 8,400 ng/mL. The aPTT remains prolonged at 72 seconds. Chromogenic factor VIII assay (human reagents) is 12%, and chromogenic factor VIII assay (bovine reagents) is 8%. Repeat Bethesda titer is 3.8 BU/mL. Which therapeutic approach is the most appropriate next step in management?", "options": ["Initiate therapeutic anticoagulation with unfractionated heparin and continue emicizumab", "Place an inferior vena cava filter and discontinue emicizumab", "Discontinue emicizumab, initiate therapeutic anticoagulation with low molecular weight heparin, and intensify immunosuppression with rituximab", "Continue emicizumab, place an inferior vena cava filter, and add cyclophosphamide to the immunosuppressive regimen", "Discontinue emicizumab, administer activated prothrombin complex concentrate for hemostatic coverage, and initiate therapeutic anticoagulation with fondaparinux"], "answer": "C", "answer_index": 2, "explanation": "This clinical scenario involves acquired hemophilia A (AHA) with the added complication of venous thromboembolism (VTE) developing in a patient on emicizumab therapy, presenting a challenging management situation. The central concern is that emicizumab produces thrombin generation via its factor VIIIa-mimetic mechanism, and the concurrent use of emicizumab with therapeutic anticoagulation or additional bypassing agents substantially elevates thrombotic risk. While the patient has an indication for anticoagulation due to pulmonary embolism, emicizumab therapy must first be stopped. The chromogenic factor VIII measurements (12% using human reagents) demonstrate ongoing emicizumab activity, though disease remission has not been attained (bovine reagent assay showing 8% with continuing inhibitor presence at 3.8 BU/mL). Low molecular weight heparin is the preferred anticoagulant over unfractionated heparin in this clinical context because it offers more consistent pharmacokinetic properties and eliminates the need for aPTT monitoring, which lacks reliability in AHA. Augmenting immunosuppressive therapy with rituximab is warranted given the insufficient response to corticosteroids alone after an 8-day period. Option A poses a contraindication due to thrombotic hazard when emicizumab is combined with anticoagulation. Option B neglects the requirement for anticoagulation in acute pulmonary embolism. Option D increases thrombotic risk by maintaining emicizumab alongside IVC filter insertion. Option E employs activated prothrombin complex concentrate (APCC), which when used with anticoagulation presents severe thrombotic risk, and fondaparinux monitoring would be challenging given the underlying coagulopathy. The essential principle is that emicizumab therapy must be halted prior to beginning therapeutic anticoagulation in AHA patients who experience VTE.", "generator_model": "claude-opus-4-5-20251101", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed131", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed131-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed131.jsonl", "pred": "D", "model_outputs": "The patient has acquired hemophilia A (AHA) with a significant factor VIII (FVIII) inhibitor. She developed a life-threatening bleeding event (retroperitoneal hematoma) and is on immunosuppression with prednisone and emicizumab for prophylaxis. The current problem is the development of bilateral subsegmental pulmonary emboli (PE), indicating venous thromboembolism (VTE).\n\nThe management must address both the VTE and the underlying AHA, balancing the risks of bleeding with the risks of thrombosis.\n\n1.  Management of Pulmonary Embolism (PE): The standard treatment for PE is therapeutic anticoagulation. However, this patient has a severe bleeding disorder (AHA with a FVIII inhibitor) and an increased risk of bleeding. Therefore, initiating systemic anticoagulation (like unfractionated heparin, LMWH, or fondaparinux) carries a significant risk of exacerbating bleeding or causing new bleeds. In patients with VTE who cannot tolerate anticoagulation due to prohibitive bleeding risk, placement of an Inferior Vena Cava (IVC) filter is a crucial mechanical measure to prevent further embolization.\n\n2.  Management of Acquired Hemophilia A (AHA):\n    *   Bleeding Prophylaxis: Emicizumab is a prophylactic treatment that bypasses the need for functional FVIII and is effective in preventing bleeds in patients with AHA. It is administered subcutaneously and does not directly interfere with standard anticoagulation therapy, nor does it typically increase thrombotic risk on its own. Therefore, continuing emicizumab for bleeding prophylaxis is logical.\n    *   Inhibitor Eradication: The goal of treating AHA is to eradicate the FVIII inhibitor. This is achieved through immunosuppressive therapy. While prednisone was initiated, the addition of more potent immunosuppressants like cyclophosphamide or rituximab is often necessary, especially for persistent or high-titer inhibitors.\n\nLet's evaluate the options based on these principles:\n\n*   A. Initiate therapeutic anticoagulation with unfractionated heparin and continue emicizumab: Unfractionated heparin significantly increases the risk of bleeding in a patient with AHA. This option prioritizes immediate anticoagulation but overlooks the severe bleeding risk.\n\n*   B. Place an inferior vena cava filter and discontinue emicizumab: Placing an IVC filter is appropriate for VTE management in a high bleeding risk patient. However, discontinuing emicizumab would remove the crucial bleeding prophylaxis, leaving the patient vulnerable to bleeds from AHA.\n\n*   C. Discontinue emicizumab, initiate therapeutic anticoagulation with low molecular weight heparin, and intensify immunosuppression with rituximab: Similar to option A, LMWH carries a significant bleeding risk in this patient. Discontinuing emicizumab is detrimental. While rituximab is a good choice for immunosuppression, the overall strategy is flawed.\n\n*   D. Continue emicizumab, place an inferior vena cava filter, and add cyclophosphamide to the immunosuppressive regimen: This option is the most balanced.\n    *   Continuing emicizumab provides essential bleeding prophylaxis.\n    *   Placing an IVC filter addresses the PE's risk of further embolization without the bleeding complications of systemic anticoagulation.\n    *   Adding cyclophosphamide intensifies immunosuppression to improve the chances of eradicating the FVIII inhibitor.\n\n*   E. Discontinue emicizumab, administer activated prothrombin complex concentrate for hemostatic coverage, and initiate therapeutic anticoagulation with fondaparinux: Discontinuing emicizumab is not advisable. Fondaparinux is an anticoagulant that increases bleeding risk. While aPCC can be used for hemostasis, it's typically for acute bleeding, not as a primary strategy for VTE management alongside anticoagulation in this complex scenario, and it also carries thrombotic risks.\n\nTherefore, option D offers the most appropriate, comprehensive, and cautious management strategy for this complex patient.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-006", "question": "A 28-year-old woman presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory evaluation reveals IgG 180 mg/dL (normal 700-1600), IgA <7 mg/dL, IgM 320 mg/dL (normal 40-230), and absent isohemagglutinins. Flow cytometry shows normal B-cell numbers but absent CD27+ memory B cells. Genetic testing reveals a hemizygous mutation in CD40LG. Her brother has similar symptoms. Which finding would be most unexpected in this patient?", "options": ["Cryptosporidium parvum cholangiopathy", "Pneumocystis jirovecii pneumonia", "Germinal center formation on lymph node biopsy", "Neutropenia", "Elevated liver enzymes"], "answer": "C", "answer_index": 2, "explanation": "This patient has X-linked hyper-IgM syndrome (HIGM1) due to CD40LG mutation, which can occur in females due to skewed X-inactivation or homozygosity. CD40L-CD40 interaction is essential for germinal center formation, class-switch recombination, and somatic hypermutation. Therefore, germinal center formation would be absent on lymph node biopsy. Cryptosporidium cholangiopathy, PCP, neutropenia (due to impaired granulopoiesis), and elevated liver enzymes (from sclerosing cholangitis or hepatitis) are all well-documented complications of HIGM1.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "C", "model_outputs": "The patient presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory findings show severely low IgG and IgA, elevated IgM, and absent isohemagglutinins. Flow cytometry reveals normal B-cell numbers but absent CD27+ memory B cells. Genetic testing shows a hemizygous mutation in CD40LG, and her brother has similar symptoms, strongly suggesting X-linked hyper-IgM syndrome (XHIM) due to CD40Ligand (CD40L) deficiency.\n\nCD40L expressed on activated T cells is crucial for T-cell dependent B-cell activation, proliferation, differentiation, class switch recombination, and germinal center formation. In CD40L deficiency, these processes are impaired.\n\nLet's analyze each option in the context of CD40L deficiency:\n\nA.  Cryptosporidium parvum cholangiopathy: Patients with severe combined immunodeficiency or defects in humoral immunity, including XHIM, are susceptible to opportunistic infections, such as Cryptosporidium. Disseminated Cryptosporidium infection can lead to cholangiopathy, causing chronic diarrhea and liver dysfunction. This is a well-recognized complication.\n\nB.  Pneumocystis jirovecii pneumonia (PJP): PJP is another common opportunistic infection in individuals with impaired immune systems, including those with defects in T-cell function or T-cell help for B cells like in XHIM, leading to both B-cell and potentially T-cell related issues. This is an expected opportunistic infection in XHIM.\n\nC.  Germinal center formation on lymph node biopsy: Germinal centers are organized structures within secondary lymphoid organs where B cells undergo affinity maturation and class switch recombination. The formation and maintenance of germinal centers are heavily dependent on the interaction between CD40L on T cells and CD40 on B cells. In CD40L deficiency, germinal centers are typically absent or severely hypoplastic. Therefore, finding normal germinal center formation would be highly unexpected.\n\nD.  Neutropenia: Autoimmune cytopenias, including neutropenia, thrombocytopenia, and hemolytic anemia, are known to occur in a significant proportion of patients with XHIM. These are often considered autoimmune complications. Therefore, neutropenia is an expected finding.\n\nE.  Elevated liver enzymes: Elevated liver enzymes can result from various complications associated with XHIM, such as chronic infections (e.g., Cryptosporidium cholangiopathy), autoimmune hepatitis, or chronic inflammation. Thus, elevated liver enzymes are an expected finding.\n\nBased on this analysis, the presence of germinal centers on lymph node biopsy would be the most unexpected finding in a patient with CD40LG deficiency and XHIM.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "source_question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251129T135352000Z_claude-opus-4-5-20251101_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251129T135352000Z_claude-opus-4-5-20251101_seed124.jsonl", "pred": "D", "model_outputs": "The patient presents with a constellation of symptoms and findings highly suggestive of Behçet's disease: recurrent oral ulcers, genital ulcers, anterior uveitis, and now a central retinal artery occlusion (CRAO) confirmed on angiography. The positive HLA-B51 further supports this diagnosis. Behçet's disease is a systemic vasculitis that can affect any blood vessel. CRAO is a severe and sight-threatening manifestation. The primary goal of treatment when a patient has experienced such a severe vascular event is to prevent further occlusive events, especially in the contralateral eye.\n\nLet's analyze the options:\nA. High-dose intravenous methylprednisolone alone: Corticosteroids are the first-line treatment for acute inflammatory flares in Behçet's disease, and high-dose intravenous steroids are indicated for severe ocular involvement and vascular complications. However, in cases of severe vasculitis like CRAO, monotherapy with corticosteroids may not be sufficient to achieve long-term remission and prevent recurrence or further complications. Steroid-sparing agents or biologics are often necessary.\n\nB. Infliximab infusion: Infliximab is a TNF-alpha inhibitor, which has demonstrated significant efficacy in managing severe Behçet's disease, particularly its vascular and ocular manifestations. While effective, it's usually initiated in conjunction with other agents or after initial stabilization, and starting it alone might not provide the rapid anti-inflammatory control needed for an acute CRAO.\n\nC. Combination of high-dose corticosteroids with cyclosporine: Cyclosporine is an effective immunosuppressant used in Behçet's disease, particularly for ocular manifestations. The combination with high-dose corticosteroids provides potent immunosuppression and is a widely accepted treatment strategy for severe Behçet's ocular disease.\n\nD. Combination of high-dose corticosteroids with infliximab or adalimumab: This option represents a very aggressive and potent therapeutic approach. TNF-alpha inhibitors, such as infliximab and adalimumab, have shown remarkable efficacy in controlling severe Behçet's disease, including sight-threatening ocular inflammation and vascular complications like CRAO. Combining high-dose corticosteroids for immediate anti-inflammatory effect with a TNF-alpha inhibitor provides robust immunosuppression to halt the ongoing vasculitis and prevent further arterial occlusions. This combination is considered highly effective and is often recommended for severe or refractory cases of Behçet's disease involving major organ systems.\n\nE. Anterior chamber paracentesis with ocular massage: Anterior chamber paracentesis is not indicated for the management of CRAO or Behçet's disease. Ocular massage is also not a treatment for this condition. These interventions are unrelated to the underlying pathology of vasculitis leading to CRAO.\n\nConsidering the severity of CRAO and the need to prevent contralateral involvement, a potent combination therapy is most appropriate. Between options C and D, TNF-alpha inhibitors have shown particular effectiveness in managing the vasculitic component of Behçet's disease that leads to arterial occlusions. Therefore, the combination of high-dose corticosteroids with a TNF-alpha inhibitor (infliximab or adalimumab) represents the most aggressive and likely most effective immediate intervention to prevent further vascular events.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-008", "question": "A 34-year-old man from the Ohio River Valley presents with 3 weeks of fever, night sweats, and 15-pound weight loss. He has a history of HIV infection with CD4 count of 45 cells/μL and is not on antiretroviral therapy. Physical examination reveals hepatosplenomegaly and diffuse lymphadenopathy. Laboratory studies show pancytopenia and LDH 1,850 U/L. Bone marrow biopsy reveals small intracellular yeast forms within macrophages. Urine Histoplasma antigen is strongly positive. He is started on liposomal amphotericin B. On day 3 of treatment, he develops high fever, hypotension, and worsening respiratory status despite negative blood cultures and improving fungal markers. Which intervention is most appropriate?", "options": ["Add voriconazole for possible amphotericin-resistant Histoplasma", "Initiate corticosteroids for immune reconstitution inflammatory syndrome", "Switch to itraconazole due to amphotericin B toxicity", "Add broad-spectrum antibiotics for bacterial superinfection", "Delay antiretroviral therapy initiation for at least 4 weeks"], "answer": "B", "answer_index": 1, "explanation": "This patient is experiencing paradoxical worsening consistent with immune reconstitution inflammatory syndrome (IRIS), which can occur in severely immunocompromised HIV patients even before ART initiation (unmasking IRIS) or represent early inflammatory response to effective antifungal therapy. The improving fungal markers argue against treatment failure or resistance. Corticosteroids (prednisone 0.5-1 mg/kg) are the treatment of choice for moderate-to-severe IRIS. While ART timing is important, the immediate management of IRIS takes precedence. Amphotericin B resistance in Histoplasma is exceedingly rare.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "B", "model_outputs": "The patient presents with severe disseminated histoplasmosis in the context of profound immunosuppression (CD4 count 45 cells/μL). He was appropriately started on liposomal amphotericin B. The development of high fever, hypotension, and worsening respiratory status on day 3 of treatment, despite negative blood cultures and improving fungal markers, is highly suggestive of an Immune Reconstitution Inflammatory Syndrome (IRIS). IRIS occurs when the immune system begins to recover after starting antiretroviral therapy (ART) or treatment for opportunistic infections, leading to an exaggerated inflammatory response to the underlying infection. Although ART has not yet been initiated, the immune system may still be showing signs of recovery or dysregulation in response to effective antifungal therapy. Steroids are the mainstay of treatment for symptomatic IRIS.\n\nLet's analyze the options:\nA. Add voriconazole for possible amphotericin-resistant Histoplasma: Resistance to amphotericin B is rare, and this presentation is more typical of an inflammatory phenomenon rather than treatment failure due to resistance.\nB. Initiate corticosteroids for immune reconstitution inflammatory syndrome: This is the most fitting diagnosis given the patient's profound immunosuppression, treatment initiation, and paradoxical worsening of inflammatory symptoms.\nC. Switch to itraconazole due to amphotericin B toxicity: While amphotericin B can cause fever, chills, and hypotension, the worsening respiratory status and the improving fungal markers suggest this is not simply direct drug toxicity. Amphotericin B is the preferred induction therapy for severe disseminated histoplasmosis, and switching is not the first step in managing an apparent IRIS event.\nD. Add broad-spectrum antibiotics for bacterial superinfection: Blood cultures are negative, making bacterial superinfection less likely as the primary driver of this specific inflammatory syndrome, although it should always be considered. However, IRIS is a more specific and likely explanation for this constellation of symptoms after starting antifungal therapy.\nE. Delay antiretroviral therapy initiation for at least 4 weeks: ART is crucial for long-term management. While ART initiation is often delayed for about 2 weeks in severe opportunistic infections to allow stabilization, the current problem is acute worsening *during* antifungal therapy. The immediate intervention needed is for the IRIS, not necessarily a decision about the ART timing right at this moment, and delaying for 4 weeks might be excessively long.\n\nThe most appropriate intervention for presumed IRIS in this setting is the administration of corticosteroids.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-009", "question": "A 58-year-old woman with metastatic HER2-positive breast cancer on trastuzumab deruxtecan develops progressive dyspnea over 4 weeks. CT chest reveals bilateral ground-glass opacities with a peripheral and lower lobe predominant distribution. Bronchoalveolar lavage shows lymphocytic predominance with CD4/CD8 ratio of 0.5. Infectious workup is negative. She is diagnosed with drug-induced interstitial lung disease. After drug discontinuation and corticosteroid initiation, her symptoms improve. Three months later, restaging shows disease progression. Which factor most strongly supports rechallenge with trastuzumab deruxtecan?", "options": ["Initial ILD grade was 1 with complete radiographic resolution", "Absence of anti-drug antibodies on serologic testing", "HER2 amplification ratio >6 on repeat biopsy", "Negative rechallenge skin testing to the drug", "Normal pulmonary function tests at baseline before rechallenge"], "answer": "A", "answer_index": 0, "explanation": "Rechallenge with trastuzumab deruxtecan after ILD is a complex decision. Per consensus guidelines, rechallenge may be considered only in patients who experienced Grade 1 ILD that completely resolved both clinically and radiographically. Higher grade ILD (Grade 2-4) is generally considered a contraindication to rechallenge. Anti-drug antibodies, HER2 status, skin testing, and baseline PFTs do not reliably predict ILD recurrence risk. The mechanism of T-DXd-associated ILD is not fully understood but appears related to the topoisomerase I inhibitor payload rather than immune-mediated hypersensitivity.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "A", "model_outputs": "A. Initial ILD grade was 1 with complete radiographic resolution\n\nThe final answer is $\\boxed{A}$"}, {"quiz_id": "ABMS20260101_claude-opus-4-5-20251101_p03", "question_id": "ABMS20260101_claude-opus-4-5-20251101_p03-010", "question": "A 42-year-old woman with a history of chronic rhinosinusitis and nasal polyps presents with new-onset asthma requiring systemic corticosteroids. She reports severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. She requires hip replacement surgery and the orthopedic surgeon requests clearance for perioperative ketorolac use. After shared decision-making, aspirin desensitization is planned. During the desensitization protocol, she develops bronchospasm at the 60 mg aspirin dose. Which mediator's urinary metabolite would be most elevated during this reaction?", "options": ["Leukotriene E4", "Prostaglandin D2 (as 11β-prostaglandin F2α)", "Histamine (as N-methylhistamine)", "Tryptase", "Platelet-activating factor"], "answer": "A", "answer_index": 0, "explanation": "Aspirin-exacerbated respiratory disease (AERD) is characterized by overproduction of cysteinyl leukotrienes (CysLTs) due to dysregulated arachidonic acid metabolism. During aspirin-induced reactions in AERD, urinary leukotriene E4 (LTE4), the stable end-metabolite of CysLTs, increases dramatically (often 3-10 fold). This distinguishes AERD from IgE-mediated reactions where prostaglandin D2 metabolites and histamine metabolites predominate. Tryptase elevation suggests mast cell degranulation in anaphylaxis but is not characteristic of AERD reactions. The CysLT pathway is the primary driver of bronchoconstriction in AERD.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy/Immunology", "source_quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/claude-opus-4-5-20251101/20251218T014545383Z_claude-opus-4-5-20251101_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251218T014545383Z_claude-opus-4-5-20251101_seed130.jsonl", "pred": "A", "model_outputs": "The patient presents with classic features of Aspirin-Exacerbated Respiratory Disease (AERD), including chronic rhinosinusitis with nasal polyps, asthma, and severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. NSAIDs inhibit the cyclooxygenase (COX) pathway, shunting arachidonic acid metabolism towards the lipoxygenase (LOX) pathway. This leads to an overproduction of potent inflammatory mediators, particularly cysteinyl leukotrienes (LTC4, LTD4, LTE4). These mediators cause bronchoconstriction, inflammation, and mucus hypersecretion.\n\nDuring aspirin desensitization, when the patient develops bronchospasm, it signifies an acute exacerbation driven by the release of these mediators.\n\nLet's evaluate the options:\nA. Leukotriene E4 (LTE4): This is a stable metabolite of cysteinyl leukotrienes and is a direct marker of increased leukotriene synthesis. In AERD, elevated urinary LTE4 levels are a hallmark of NSAID-induced reactions and are significantly increased during challenges with aspirin or other NSAIDs.\nB. Prostaglandin D2 (PGD2) (as 11β-prostaglandin F2α): PGD2 is a product of the COX pathway. NSAIDs *inhibit* COX, so PGD2 production would be *decreased*, not elevated, in the context of this NSAID-induced reaction.\nC. Histamine (as N-methylhistamine): While mast cell activation, which releases histamine, can be a component of hypersensitivity reactions, the primary and most significant mediators driving the bronchospasm in AERD are cysteinyl leukotrienes. Histamine metabolites are not typically considered the *most* elevated mediators in this specific NSAID-induced phenomenon.\nD. Tryptase: Tryptase is released by mast cells. While mast cell degranulation occurs, it's not the direct cause of the specific NSAID-induced airway inflammation seen in AERD as much as the leukotrienes. It's not the most specific or elevated mediator in this context compared to leukotrienes.\nE. Platelet-activating factor (PAF): PAF is another inflammatory mediator that can contribute to airway inflammation. However, the overproduction of cysteinyl leukotrienes is considered the predominant mechanism in NSAID-induced bronchospasm in AERD.\n\nTherefore, leukotriene metabolites, specifically LTE4, are expected to be the most elevated during this acute reaction.\n\nThe final answer is $\\boxed{A}$."}]